Introduction: The HeartMate 3 ™ has shown lower rates of adverse events compared to previous devices due to the design and absence of mechanical bearings. For previous devices, sound analysis emerged as a way to assess pump function. The aims of this study were to determine if sound analysis can be applied to the HeartMate 3 in vivo and in vitro and to evaluate an electronic stethoscope. Method: Sound recordings were performed with microphones and clinical accessible electronic stethoscope. The recordings were studied in both the time and the frequency domains. Recordings from four patients were performed to determine if in vivo and in vitro recordings are comparable. Results: The results show that it is possible to detect sound from HeartMate 3 and the sound spectrum is clear. Pump frequency and frequency of the pulsatile mode are easily determined. Frequency spectra from in vitro and in vivo recordings have the same pattern, and the major proportion (96.7%) of signal power is located at the pump speed frequency ±40 Hz. The recordings from the patients show low inter-individual differences except from location of peaks originating from pump speed and harmonics. Electronic stethoscopes could be used for sound recordings, but the dedicated equipment showed a clearer sound spectrum. Discussion: The results show that acoustic analysis can also be performed with the HeartMate 3 and that in vivo and in vitro sound spectrum is similar. The frequency spectra are different from previous devices, and methods for assessing pump function or thrombosis need further evaluation.
Introduction
The outcome of patients treated with left ventricular assist devices (LVADs) has improved in recent decades due to improved patient selection, management, and the introduction of continuous flow pumps. Despite this, adverse events such as infection, bleeding, and pump thrombosis still occur. 1, 2 The HeartMate 3 ™ (Abbott, Lake Bluff, IL, USA) (HM 3) is a compact intrapericardial centrifugal-flow pump that uses magnetic levitation and therefore eliminates the need for mechanical bearings. It was developed to enhance hemocompatibility and minimize the shear stress that resulted in acquired von Willebrand syndrome associated with previous LVAD models. [3] [4] [5] Results from the initial trials and follow-up studies, up to 2 years, showed superiority compared to the axial-flow HeartMate II (Abbott) (HM II) with improved clinical outcome due to a lower reoperation rate, lower overall stroke rate, and low reports of pump thrombosis within the device. [6] [7] [8] [9] [10] [11] [12] In recent years, sound analysis has emerged as a novel, non-invasive way to monitor and evaluate pump function in pulsatile, axial, and centrifugal LVADs. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Presence of a third harmonic and an increase in pump frequency amplitude has been shown to be a sign of thrombosis in other centrifugal LVADs. 18, 20 In a recent study, the number of amplitudes was correlated to the presence of thrombosis. 23 The HM II has a different sound spectrum due to its design. 21, 22 However, the sound may be analyzed, and in vitro studies and in vivo cases have shown that pump function and presence of thrombosis can be assessed with a change in amplitude indicating thrombosis. 17, 21 The electronic stethoscope has been used in multiple studies on sound analysis from LVAD, but the reliability of this device has never been discussed. 19, 21 The sound from HM 3, with its fully magnetic levitation, has never been characterized.
The aim of this study is to characterize and evaluate the sounds from HM 3, if they can be recorded and if in vivo and in vitro acoustic analyses are comparable. A further aim was to evaluate whether an electronic stethoscope may be used for recording audio signals from the HM 3.
Method

Study settings
Properties of the HM 3 are briefly described elsewhere. 8 The HM 3 is powered by a 14-V lithium-ion battery and operates between 10 and 17 V. The winding type and numbers of stators are not accessible.
Mock loop
An experimental model was setup with a HM 3 in a mockloop circuit with the pump housing immersed in a bag of saline. This setup ensures a dry surface for recording purposes and a surface to pump distance that is comparable to the position of the HM 3 within the thoracic cavity, approximately 2 cm (0.78 in). The pump was connected to a 2-L (67.6 oz) water chamber, with a 50-cm (19.6 in) plastic tubing 2 cm (0.78 in) in inner diameter, connecting the chamber to the pump inflow. The graft from the HM 3 connected the pump outflow and the chamber (see Supplemental Material). The pump speed was increased from 3000 r/min (rpm) to 8000 r/min in increments of 100 r/min, and recordings were made after each increase. The HM 3 creates a pulsatile flow by alternating the speed 30 times per minute (see Supplemental Material). This pattern begins when the fixed speed setting is set at a minimum of 4000 r/min. The pump introduces a quick frequency change twice per second. The pump frequency is decreased for 0.15 s and then increased for 0.2 s. Both changes are instantaneous as step functions (see theoretical spectrum as Supplemental Material). To simulate obstruction, hemostatic forceps were used to create a constant narrowing of the inflow and outflow conduits to approximately 50%. To determine if the recorded soundwaves were due to surrounding sounds, flow or pump oscillation, an abrupt pump stop was performed.
The recording devices were placed on the surface of the saline bag. The microphones were placed with the diaphragms facing toward the pump and the windscreen touching the surface of the saline bag with an approximate angle of 90°.
Patients
To be able to compare the acoustics from the mock loop circuit, sound was recorded from four consecutive patients with a HM 3. The study complies with the Declaration of Helsinki and was approved by regional ethics review board in Linköping University Hospital (Dnr 2011/282-31, 2019-00415). All patients gave informed consent, and no clinical adjustments or change in any pump setting was made during the recording sessions to ensure no risk for adverse events.
The recording devices were placed on skin surface above the pump house and lateral of the left midclavicular line in intercostal space 8-9. The microphones were placed with the diaphragms facing toward the pump and the windscreen touching the skin with an approximate angle of 90°.
Recording devices and software
Two microphones, Shure PG58 (Shure Inc. Niles, IL, USA), were connected to an external sound card, and Behringer FCA1616 (Behringer, Germany) was connected to a commercial laptop. For full technical specification, see product specification. 24, 25 The microphones were placed adjacent to each other to determine if there were any inter-individual differences between the recordings. Multiple 10-s clips were recorded. The same microphones were used for in vivo and in vitro recordings, and no changes in settings of the external sound card were performed. These microphones have previously been used and shown to be acceptable for sound recording of LVAD. 22 A Littmann ™ 3200, electronic stethoscope (3M, St. Paul, MN, USA) was also used. The electronic stethoscope is capable of recording sounds in the frequency range 20-2000 Hz with multiple 30-s clips. Three filters may be applied, of which we used the extended filter that amplifies sounds between 20 and 2000 Hz, but emphasizes frequencies of 50-500 Hz. The audio recordings were then transferred by Bluetooth to a computer with the Littmann StethAssist (3M) software. The same stethoscope was used for in vivo and in vitro recordings, and the extended filter was used for all recordings. The sampling rate was set at 44.1 kHz for the microphones and 4 kHz for the Littmann 3200
Recordings with the Shure microphones and all analyses were performed using MATLAB (Mathworks, Natick, MA, USA), and the same functions were used for both the stethoscope and the microphones. 26 
Statistical analysis
Statistical analysis was performed with the use of IBM SPSS, version 23. To determine correlation between measured and estimated frequencies, the Pearson correlation coefficient was calculated. When assessing the difference between the in vitro and in vivo signal, all recordings for each patient and the recordings in mock loop at the same speed were assessed for estimated frequency and power distribution within the pump frequency ±40 Hz. The student's t-test was used to calculate difference between in vivo and in vitro recordings. Two-tailed p values of less than 0.05 are considered to indicate statistical significance.
Recording analysis
First, the recording was plotted as a function of time in MATLAB. Thereafter, customized software computed the estimated frequency by performing fast Fourier transform analysis and automatic finding of the highest peak. A Hamming window, built in as standard in MATLAB functions, reduced the disruptive effect in the truncated time history. A window size of 1024 samples was used. To minimize differences in sound volume between different patients and recordings, normalization was performed where the total area under curve was set to 1 W. This generates small numbers of W/Hz and −20 dB equals to 0.01 W/Hz. Power spectral density (PSD) was computed to assess the distribution of signal power over various frequencies that could be of interest. Furthermore, the PSD was used to verify the LVAD frequency defined in the setup to determine reliability.
Results
In vitro recordings
The function of HM 3 was assessed by increasing speed and comparing speed toward pulsatility index (PI), flow read from the monitor, and power. The results showed significant correlation, (p < 0.01 for correlation) as expected.
When the sounds from the HM 3 were plotted as a function of time, a sine wave was seen (Figure 1 ). When recording at pump speeds above 4000 r/min, that is, the point at which the pulsatile mode used by the HM 3 is activated, a change in amplitude and frequency in the sound signal as a function of time was detected. The changes in amplitude and frequencies were detectable when using the electronic stethoscope but not as clear as with the dedicated equipment (Figure 1) .
When the PSD of the sound was plotted over the entire frequency spectrum, the highest power was present in the lower frequency range with a mean of 96.7% within ±40 Hz of the pump frequency (rpm/60). There was no significant frequency component in the higher frequency range, but clearly visible harmonics of the pump speed could be seen in the low frequency spectrum (Figure 2 ). The frequency interval was chosen to include the pump frequency and the frequency of the artificial pulse. Above 4000 r/min, symmetrically centered peaks around the pump frequency were detected. These represent modulations due to the increase and decrease in speed used to generate the pulsatile flow ( Figure 2) .
These findings were clearly detected with the Shure microphones when plotted in a frequency spectrum. They could be detected with the electronic stethoscope as well, but they were not as clear ( Figure 2 ). The peaks from pulsatile mode appeared at a mean of +29.5 Hz/-30.5 Hz from pump frequency, corresponding to a change in speed of approximately 1800 r/min. The peaks that represent a reduction in speed correspond to a mean of 4.3% of the power, and the peaks that represent increased speed correspond to 18% of the total power. The higher amount of power for the increase is since the increase lasts for 0.2 s, while the decrease lasts for 0.15 s. This indicates that most of the signal is within the fundamental frequency (pump frequency) and the increment due to pulsation and that this signal and harmonics are due to the system function.
The largest peak in the PSD was significantly correlated to the set fixed speed, showing a linear relationship with the Shure microphones (p < 0.0001). The electronic stethoscope determined the correct pump speed in approximately 50% of recordings with the peak from pump speed clearly visible but another peak with higher PSD.
When the pump was suddenly turned off by unplugging the controller, the alarm signal appeared after exactly 0.5 s and greatly affected the signal in time domain. The recording of the HM 3 at this point revealed that pump rotation terminated abruptly and no continuous oscillation in time domain was seen. This indicates that the magnetic rotor does not produce any further rotation and is abruptly stopped and most likely fixed to one of the magnetic stators (Figure 3 ). When the inflow and outflow were obstructed, there was no change in the frequency or in the time domain, except a small increase in the first harmonic, but the flow rate on the monitor dropped and the pump signaled for low flow after a few seconds (see Supplemental Material).
HM 3; In vivo recordings
When comparing in vivo recordings with in vitro recordings using the Shure microphones, there was no significant difference between estimated speed in the patients and estimated pump speed in the mock loop circuit (p = 0.88 for difference between groups). When using the electronic stethoscope in vivo, results were not consistent with pump speed estimated with the microphones and with the electronic stethoscope in the mock loop circuit. When comparing signals from the Both devices show the estimated pump frequency (dotted line) and harmonics (black lines). The decrease in frequency due to artificial pulsation (dotted thin line) is not as clear with the electronic stethoscope and the spectrum holds more interference; -20 dB equals to 0.01 W/Hz. mock loop circuit with those from the four patients, in time domain, the sine wave, change in frequency, and amplitude of the spectrum were similar except for a small amplitude difference in the harmonics (Figure 4) .
When comparing the power distribution within the frequency spectrum, there was no statistical significant difference between the in vitro and in vivo recordings ( Figure 5 ).
Discussion
HM 3 represents a new generation of LVAD that shows great potential, with low risk for pump thrombosis and other hemo-incompatibility-related adverse events. [6] [7] [8] 11 The previous LVADs were associated with complications of which pump thrombosis has been frequently addressed. [27] [28] [29] The etiology of pump thrombosis is multifactorial, and the phenomenon is related to multiple risks. 30 The design of the HM 3 is different to previous pump systems, and due to magnetic levitation, the distance between the rotor and wall is greater, minimizing the risk for pump thrombosis. 8 The incidence of pump thrombosis in HM 3 is rare, indicating the importance of more diagnostic possibilities. 31 The absence of mechanical bearings results in a clear sine wave with few disturbances visible on audio recordings using both dedicated equipment and the electronic stethoscope. The use of sound analysis as a way to detect malfunction and assess thrombosis has been developed and applied to previous pumps with encouraging results. 17, 18, 20, 21 In this study, sound signals from the HM 3 were characterized, and the results indicate that sound analysis may be used as one of the tools to evaluate pump function in this system in the same way as with previous systems and that future studies on evaluation on pump function and changes in frequency and time domain during different clinical circumstances initially can be performed in vitro and thereafter verified in vivo studies. Compared to the HM II, the HM 3 has a more distinct frequency spectrum where peaks and harmonics are clearly seen. The frequency spectrum from the HM 3 resembles the ones from other centrifugal pumps in which sound analysis has shown changes in the frequency spectrum caused by the presence of thrombosis, a change in amplitude and the presence of a peak at three times the pump frequency were significant findings. 18, 20 With the HM 3, a peak at three times the pump frequency was seen in both the mock loop circuit simulation and in recordings from actual patients. This would suggest that the same findings might also be valid for the HM 3 but with increases in amplitude or increase in number of peaks as recently seen. 23 Perhaps, a change in the power distribution or amplitude of specific peaks is more valid, but this remains to be studied and future clinical studies are ongoing. Function of the pulsatile mode was easily assessed by sound analysis, and according to frequency analyses, the change in speed is ±1800 r/min. This result differs from the interval delivered from the manufacturer but might be valid since the intervals were consistent for all our recordings.
In this study, we used both dedicated recording equipment and an electronic stethoscope to record HM 3 sounds. The reason was to evaluate the electronic stethoscope. Both equipment could be used to create a valid signal in both time and frequency domain. However, the dedicated recording equipment showed clearer signals and were more accurate in determining pump frequency in both in vivo and in vitro recordings, indicating that the results found in studies with the electronic stethoscopes must be validated with more reliable equipment. 19, 21 The electronic stethoscope's main advantage is the accessibility as a clinical instrument and therefore it might be used as a screening tool in the clinical setting. If there is an indication of malfunction, a more thorough recording should be performed. The relative low sample rate of the stethoscope also results in its inability to assess frequencies higher than 2 kHz, according to the sampling theorem. In one patient, the sound recording was performed at the intensive care unit, resulting in disturbance, that might have affected the analysis to some extent, but the spectra were still similar. A limitation of this study is the lack of results from mock loop simulation of pump thrombus, but the study lays the foundation for future studies where simulation of thrombosis in different location could be one application. Another limitation of the study is the small number of in vivo recordings. However, we performed multiple recordings in each patient, and they all were similar, indicating reproducibility. The results imply that future research into the sound analysis of thrombosis, for instance, can be performed in vitro and thereafter studied and verified in vivo. This approach can minimize the risk to patients and minimize the use of animal research. Further research on sound analyses of the HM 3 is necessary to determine the specific changes related to thrombosis and mechanical failure, but this study points out the possibilities to perform such studies in mock loop circuits. If specific parameters in the acoustic spectra are found, as for instance number of peaks or a peak at a specific frequency, the stethoscope can be adjusted and artificial intelligence added, and by that be used for identifying thrombosis or mechanical problems. 
